Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

Pfizer logo

Pfizer

Status and phase

Completed
Phase 3

Conditions

Infections, Nosocomial

Treatments

Drug: linezolid

Study type

Interventional

Funder types

Industry

Identifiers

NCT00150332
A5951054
M12600067

Details and patient eligibility

About

Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan

Enrollment

24 patients

Sex

All

Ages

16+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

infection due to methicillin-resistant Staphylococcus aureus

Exclusion criteria

hypersensitivity to linezolid

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

20

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems